Colchicine for Patients With Coronary Artery Disease: A Systematic Review and Meta-analysis.

Autor:	Shrestha DB; Department of Internal Medicine, Mount Sinai Hospital, Chicago, IL., Budhathoki P; Department of Internal Medicine, Bronxcare Health System, Bronx, NY., Sedhai Y; Department of Internal Medicine, Division of Hospital Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA., Khadka M; Nepalese Army Institute of Health Sciences (NAIHS), Kathmandu, Nepal., Pokharel S; Nepalese Army Institute of Health Sciences (NAIHS), Kathmandu, Nepal., Yadav S; Nepalese Army Institute of Health Sciences (NAIHS), Kathmandu, Nepal., Patel T; Department of Internal Medicine, Division of Cardiology, AdventHealth-AdventHealth Medical Group at East Orlando, Orlando, FL., Elgendy I; Department of Internal Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar ; and., Mir WAY; Department of Internal Medicine, Mount Sinai Hospital, Chicago, IL., Patel NK; Department of Internal Medicine, Division of Cardiology, VCU Pauley Heart Center, Virginia Commonwealth University, School of Medicine, Richmond, VA.
Jazyk:	angličtina
Zdroj:	Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2022 Apr 01; Vol. 79 (4), pp. 420-430.
DOI:	10.1097/FJC.0000000000001200
Abstrakt:	Abstract: Several randomized controlled trials have studied the role of colchicine, a potent anti-inflammatory drug, to prevent adverse cardiovascular events in patients with coronary artery disease (CAD). In this meta-analysis, we aimed to determine the role of colchicine in patients with CAD in clinical outcomes and mortality. We searched PubMed, PubMed Central, Scopus, and Embase for randomized controlled trials/experimental studies evaluating the role of colchicine in patients with CAD. After assessing the eligibility for inclusion, risk-of-bias assessment, and data extraction from the included studies, a narrative synthesis was conducted. Of 17 studies included for the qualitative analysis, 11 studies reported that inflammatory markers such as C-reactive protein and cytokines were reduced in the colchicine group, suggesting an anti-inflammatory role of colchicine in CAD. Quantitative analysis with pooling of data from 9 studies using a fixed-effect model showed 28% lower odds of acute myocardial infarction [odds ratio (OR) 0.72, 95% CI 0.59-0.86; n = 11,712], 52% lower occurrence of stroke (OR 0.48, 95% CI 0.30-0.76), and 37% reduction in odds of coronary revascularization procedure in the colchicine group (OR 0.63, 95% CI 0.52-0.76; n= 11,258). However, the odds of gastrointestinal adverse events were 50% higher in the colchicine group (OR 1.50, 95% CI 1.01-2.23; n = 12,214). In conclusion, colchicine is associated with a lower risk of acute myocardial infarction, stroke, and coronary revascularization. However, there is some increased risk of gastrointestinal adverse events with the use of colchicine. Competing Interests: The authors report no conflicts of interest. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu